DOCSLIB.ORG

FORM 5 QUARTERLY LISTING STATEMENT Name of Listed Issuer

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
FORM 5 QUARTERLY LISTING STATEMENT Name of Listed Issuer FORM 5 QUARTERLY LISTING STATEMENT Name of Listed Issuer: MPX International Corporation (“MPXI” or the “Issuer”). Trading Symbol: MPXI This Quarterly Listing Statement must be posted on or before the day on which the Issuer’s unaudited condensed interim financial statements are to be filed under the Securities Act, or, if no interim statements are required to be filed for the quarter, within 60 days of the end of the Issuer’s first, second and third fiscal quarters. This statement is not intended to replace the Issuer’s obligation to separately report material information forthwith upon the information becoming known to management or to post the forms required by the Exchange Policies. If material information became known and was reported during the preceding quarter to which this statement relates, management is encouraged to also make reference in this statement to the material information, the news release date and the posting date on the Exchange website. Currency Unless otherwise stated, all dollar amounts are expressed in Canadian dollars. General Instructions (a) Prepare this Quarterly Listing Statement using the format set out below. The sequence of questions must not be altered nor should questions be omitted or left unanswered. The answers to the following items must be in narrative form. When the answer to any item is negative or not applicable to the Issuer, state it in a sentence. The title to each item must precede the answer. (b) The term “Issuer” includes the Listed Issuer and any of its subsidiaries. (c) Terms used and not defined in this form are defined or interpreted in Policy 1 – Interpretation and General Provisions. There are three schedules which must be attached to this report as follows: SCHEDULE A: FINANCIAL STATEMENTS Financial statements are required as follows: For the first, second and third financial quarters interim financial statements prepared in accordance with the requirements under Ontario securities law must be attached. If the Issuer is exempt from filing certain interim financial statements, give the date of the exempting order. FORM 5 – QUARTERLY LISTING STATEMENT January 2015 Page 1 SCHEDULE B: SUPPLEMENTARY INFORMATION The supplementary information set out below must be provided when not included in Schedule A. 1. Related party transactions Provide disclosure of all transactions with a Related Person, including those previously disclosed on Form 10. Include in the disclosure the following information about the transactions with Related Persons: (a) A description of the relationship between the transacting parties. Be as precise as possible in this description of the relationship. Terms such as affiliate, associate or related company without further clarifying details are not sufficient. (b) A description of the transaction(s), including those for which no amount has been recorded. (c) The recorded amount of the transactions classified by financial statement category. (d) The amounts due to or from Related Persons and the terms and conditions relating thereto. (e) Contractual obligations with Related Persons, separate from other contractual obligations. (f) Contingencies involving Related Persons, separate from other contingencies. See Note 26 in the Unaudited Interim Condensed Consolidated Financial Statements of the Issuer for the three and nine month period ended June 30, 2021 (the “Financial Statements”). 2. Summary of securities issued and options granted during the period. Provide the following information for the period beginning on the date of the last Listing Statement (Form 2A): (a) summary of securities issued during the period, FORM 5 – QUARTERLY LISTING STATEMENT January 2015 Page 2 Date of Type of Security Type of Issue (private Number Price Total Proceeds Type of Describe Commission Issue (common placement, public Consideration relationship of Paid shares, offering, exercise of (cash, Person with convertible warrants, etc.) property, etc.) Issuer (indicate debentures, etc.) if Related Person) Apr 21-21 Debentures Loan (1) 1,312,500 $1.00 $1,312,500.00 Cash Officers and None Directors of MPXI Participated in this Loan Apr 21-21 Bonus Warrants Incentive to Participate 11,937,376 $0.20 N/A Loan Officers and None in the Loan (2) Directors of MPXI Received Bonus Warrants Apr 30-21 Debentures Loan (3) 1,262,500 $1.00 $1,262,500.00 Cash None None Apr 30-21 Bonus Warrants Incentive to Participate 11,482,615 $0.20 N/A Loan None None in the Loan (4) May 25-21 Common Shares Warrant Exercises (5) 267,098 (1) Nil N/A Cashless A Director of None MPXI Exercised Warrants May 25-21 Common Shares Commission Warrant 136,255 (2) Nil N/A Cashless None Exercises (6) May 25-21 Warrants Commission Warrant 68,126 (2) Nil N/A Cashless None Exercises (6) May 25-21 Common Shares Warrant Exercises (6) 68,126 (2) Nil N/A Cashless None Jun 30-21 Units, comprised Private Placement (7) 248 $1,360.00 $337,280.00 Cash Officers and None of Secured Directors of Convertible MPXI Debentures and Participated in Warrants this tranche of the Offering Notes: (1) On April 21, 2021, the Issuer completed the first draw down (the “1st Draw Down”) of short-term loan financing (the “Initial Bridge Loan”) from a group of current investors in the amount of $1,312,500. On August 27, 2021, the principal amount of the Initial Bridge Loan automatically converted into Units (as defined below) of the Offering (as defined below) at a conversion premium equal to ten percent (10%) of their principal amount. (2) On April 21, 2021, 11,937,376 Bonus Warrants were issued to certain Bridge Loan lenders advancing funds in the 1st Draw Down of the 1st Draw Down of the initial Bridge Loan. (3) On April 30, 2021, the Issuer completed the second draw down (the “2nd Draw Down”) of short-term loan financing (the “Initial Bridge Loan”) from a group of current investors in the amount of $1,262,500. On August 27, 2021, the principal amount of the Initial Bridge Loan automatically converted into Units (as defined below) of the Offering (as defined below) at a conversion premium equal to ten percent (10%) of their principal amount. (4) On April 30, 2021, 11,482,615 Bonus Warrants were issued to certain Bridge Loan lenders advancing funds in the 1st Draw Down of the 1st Draw Down of the initial Bridge Loan. (5) On May 25, 2021, 267,098 common share purchase warrants, which became obligations of the Issuer as part of the plan of arrangement (the “Arrangement”) in February 2019 among the Issuer, MPX Bioceutical Corporation and iAnthus Capital Holdings Inc., were exercised into common shares of the Issuer. (6) On May 25, 2021, 136,255 commission warrants, which became obligations of the Issuer as part of the Arrangement, were exercised into units with each unit consisting of 1 common share and ½ common share purchase warrant (the “Warrants”). Upon issuance, the Warrants were immediately exercised into 68,126 common shares. FORM 5 – QUARTERLY LISTING STATEMENT January 2015 Page 3 (7) On June 30, 2021, the Issuer completed the eighth tranche (the “8th Tranche”) of a non-brokered private placement offering (the “Offering”) of units (the “Units”). Each Unit consists of one 12% secured convertible debenture of the Issuer (a “Debenture”) in the principal amount of US$1,000.00 (the “Principal Amount”) and 7,000 common share purchase warrants (each, a “Warrant”). The Debentures will have a maturity date of twenty-four (24) months, subject to certain conversion privileges (the “Maturity Date”) as set forth in a debenture indenture (the “Debenture Indenture”) entered into with AST Trust Company (Canada) (“AST”). The closing of the Seventh Tranche resulted in the issuance of 248 Units at a price of $1,360 (US$1,000) for aggregate gross proceeds of $337,280 (US$248,000). Each Debenture shall bear interest at a rate of 12% per annum from the date of issue, payable quarterly in arrears on the last day of March, June, September and December in each year (each, a “Coupon Date”). All accrued but unpaid interest as of each Coupon Date shall be payable by the Issuer in cash and shall accrue interest at a rate of 12% per annum. The Principal Amount shall be convertible for no additional consideration, into common shares of the Issuer (the “Common Shares”) at the option of the holder at any time prior to the earlier of: (i) 6:00 p.m. (Eastern Standard Time) on the Maturity Date; or (ii) the business day immediately preceding the date specified by MPXI for redemption of the Debentures at a conversion price equal to $0.12 per Common Share. It is a condition of the Offering that the Issuer execute and deliver a guarantee and certain security documents in favour of AST, as collateral agent, as security for the payment and performance of the Issuer’s obligations under the Debenture Indenture. The Issuer also provided certain EBITDA covenants, agreed not to create, incur, assume or be liable for any indebtedness other than permitted indebtedness and the Debenture contains other default covenants consistent with this type of debt transaction. Each Warrant entitles the holder thereof to purchase one Common Share (each, a “Warrant Share”) at an exercise price of $0.20 (the “Exercise Price”) for a period of twenty-four (24) months (the “Expiry Date”). The Issuer and AST entered into a warrant indenture (the “Warrant Indenture”) pursuant to which the Warrants were created and issued. (b) summary of options granted during the period, Date Number Name of Optionee Generic description of Exercise Price Expiry Date Market Price if Related Person other Optionees on date of and relationship Grant Apr 16-21 1,250,000 Jeremy Blumer Director and Officer $0.20 Apr 16-26 $0.115 Apr 16-21 2,000,000 W.
Load more

Recommended publications
  • SUU Alm.Del Bilag 444: Itamar Grotto
    Sundheds- og Ældreudvalget 2017-18 SUU Alm.del Bilag 444 Offentligt MINISTRY OF HEALTH Medical Grade Cannabis - The Israeli Roadmap to Medicalization Prof. Itamar Grotto Associate Director General, Israeli Ministry of Health Medical Grade Cannabis - MINISTRY The Israeli Roadmap to Medicalization OF HEALTH Medical use of Cannabis in ancient times • 5000 years ago in Egyptian tombs • 2700 years ago in India • 2000 years ago in China for the treatment of pain Medical Grade Cannabis - MINISTRY The Israeli Roadmap to Medicalization OF HEALTH International - Single Convention on Narcotic Drugs 1961 The Cannabis plant is subject to additional measures of control Israel - The Dangerous Drug Ordinance [New Version] - 1973 The Cannabis plant and its products are defined as narcotic substances They are not registered as medicinal products Medical Grade Cannabis - MINISTRY The Israeli Roadmap to Medicalization OF HEALTH The Government of Israel Resolutions Government Resolution 3609 (7.8.2011) • Establishes the obligation of the Ministry of Health to serve as “Government Agency” for Cannabis • The multi-ministerial Stirring Committee • The Israeli Medical Cannabis Agency (IMCA) is established Government Resolution 1050 (15.12.2013) • Improving efficiency of prescription, indication inspection, appointing of Physicians and accessibility to service. • Search for feasibility of export • Regulating research. Medical Grade Cannabis - MINISTRY The Israeli Roadmap to Medicalization OF HEALTH Government Resolution 1587 (26.6.2016) - Cannabis for medical purpose and research The “Medicalization” of Cannabis Medical Grade Cannabis - MINISTRY The Israeli Roadmap to Medicalization OF HEALTH The Vision of The Israeli Medical Cannabis Agency (IMCA) To support the use of Cannabis for medical purposes exclusively, while preventing misuse and keeping public safety.
    [Show full text]
  • Israeli Cannabis Company 'Together' Announced an Agreement with a Canadian Company to Sell 50 Tons of Cannabis Inflorescences Or 5 Tons of Cannabis Oil
    Israeli cannabis company 'Together' announced an agreement with a Canadian company to sell 50 tons of cannabis inflorescences or 5 tons of cannabis oil The company estimates the potential annual revenue from the deal at hundreds of millions of shekels. "This agreement joins other existing sales agreements in Canada and German totaling 30 tons. These agreements ensure the creation of revenue and cash flow that are not dependent on export approval from the State of Israel, and which will derive from the sale of medical cannabis and its products from areas that we will set up in countries outside of Israel that have the relevant export agreements", said Globus Pharma founding partner Nissim Bracha Israel, Ashkelon, April 11 2018 – 'Together' (TASE: TGTR) announced that its activity company 'Globus Pharma', which specializes in the medical cannabis sector and operates as a subsidiary of 'Together', has signed a Memorandum of Understanding (MoU) to sell medical cannabis or oil to a Canadian company with a license to grow, produce and import medical cannabis to Canada. Under the terms of the agreement, the Canadian company will buy from Globus 50 tons of dried inflorescences of cannabis each year or five tons of medical cannabis oil (the equivalent amount to 50 tons of inflorescences) as part of the terms of the law in Canada and in Israel. In addition, the two companies will collaborate in the field of R&D and promoting technologies in the medical cannabis sector. As of the date of signing the agreement, the parties estimate that sales revenue will amount to between US$3.17 and US$4.7 per gram of inflorescence.
    [Show full text]
  • Roots Sustainable Agricultural Technologies Ltd Arbn 619 754 540 Notice of Annual General Meeting
    ROOTS SUSTAINABLE AGRICULTURAL TECHNOLOGIES LTD ARBN 619 754 540 NOTICE OF ANNUAL GENERAL MEETING Notice is given that the Meeting will be held at: TIME: 2:30 pm (WST) DATE: Thursday, 16 September 2021 PLACE: Suite 2, Level 1 1 Altona Street WEST PERTH WA 6005 The business of the Meeting affects your shareholding and your vote is important. This Notice of Meeting should be read in its entirety. If Shareholders are in doubt as to how they should vote, they should seek advice from their professional advisers prior to voting. The Directors have determined pursuant to Regulation 7.11.37 of the Corporations Regulations 2001 (Cth) and to section 182 of the Companies Law and the regulations promulgated thereunder, that the persons eligible to vote at the Meeting are those who are registered Shareholders at 5:00pm (WST) on 14 September 2021. BUSINESS OF THE MEETING AGENDA 1. FINANCIAL STATEMENT AND REPORTS Review and discussion of the audited annual financial report of the Company for the financial year ended 31 December 2020 together with the declaration of the directors, the director’s report and the auditor’s report. 2. RESOLUTION 1 – APPOINTMENT OF AUDITORS To consider and, if thought fit, to pass, with or without amendment, the following resolution: “RESOLVED, that BDO – Ziv Haft be, and hereby is, appointed as the independent auditors of the Company for the year 2021 and for an additional period until the next annual general meeting.” The affirmative vote of at least a majority of the voting power represented at the Meeting, in person or by proxy and voting thereon, is required to adopt this Resolution.
    [Show full text]
  • 2020 Global Report on Cannabis Policy
    2020 Global Report on Cannabis Policy June 2020 2 i Contents INTRODUCTION II U.S.A. - WASHINGTON 86 BRAZIL 1 OUR MEMBERS 91 CANADA 12 CONTRIBUTORS 92 CHINA 20 COLOMBIA 25 GERMANY 31 ITALY 37 PAR AGUAY 42 PERU 46 SOUTH AFRICA 54 SPAIN 59 THAILAND 65 URUGUAY 70 U.S.A. - CALIFORNIA 76 U.S.A. - OREGON 81 Global Report on Cannabis Policy 3 ii WLG CANNABIS GUIDE INTRODUCTION We are very pleased to announce the release of the World Law Group (“WLG”) Cannabis Guide 2020. In recent years, cannabis and products with cannabis components are one of the “hot topics” in the life sciences industry. Many countries now allow the medical use of cannabis to treat numerous conditions, including chronic pain, cancer, multiple sclerosis, and many others. Additionally, more and more countries have recently allowed the recreational use of cannabis. Finally, hemp (cannabis grown without mind-altering substances), is another burgeoning industry worldwide. Though there are international treaties in place, the production, distribution, and consumption of controlled substances (including cannabis) are still traditionally regulated by each country individually (even within the EU). Some countries still consider cannabis a dangerous illicit substance. Thus the legal landscape on cannabis and cannabis products is very fragmented and complicated, making it hard to get involved in the cannabis industry. The aim of this guide is to provide a brief overview of laws and policies regarding the use of cannabis in various jurisdictions. It briefly outlines information on the most important legal issues, from relevant legislation and general information to special requirements and risks.
    [Show full text]
  • Israel Takes the Next Steps Towards Legalizing Recreational Cannabis
    Article Cannabis Law July 2020 Israel Takes the Next Steps Towards Legalizing Recreational Cannabis By Andrew J. Wilder and Jonathan Mahoney Israel is considered one of the global leaders in medical cannabis research and innovation. In 1964, Professor Raphael Mechoulam of the Hebrew University of Jerusalem was the first person to isolate and identify THC, the psychoactive chemical component in cannabis that causes a high. While limited use of cannabis for medicinal purposes has been permitted in Israel since the early 1990s, it took 53 years from Professor Mechoulam’s breakthrough before the Public Security Ministry partially decriminalized cannabis in 2017, setting fines and treatment for initial offenders instead of criminal procedures. Earlier this year, after much bureaucratic delay, the export of medical cannabis was finally approved and is estimated to generate hundreds of millions of dollars in revenue annually. Now, three years since its decriminalization, Israel is on the verge of legalizing cannabis for recreational use. On June 9th, 2020, just one week after the State of Israel police minister declared that enforcement of the existing laws related to cannabis possession and use would be relaxed, two of Israel’s largest political parties issued a joint statement, agreeing to move forward with cannabis law reform. In the joint statement provided by Likud Prime Minister Benjamin Netanyahu and Blue and White’s Defense Minister Benny Gantz, they advised that reform to existing legislation was required with the aim to “resolve the issue of decriminalization and legalization” of cannabis in Israel. In addition to legalizing recreational cannabis, the proposed reforms will also make it easier for patients to gain access to treatment and for producers to become licensed to grow and sell medical cannabis.
    [Show full text]
  • Bol-Pharma-Prospectus.Pdf
    A copy of this preliminary prospectus has been filed with the securities regulatory authorities in each of the provinces and territories of Canada but has not yet become final for the purpose of the sale of securities. Information contained in this preliminary prospectus may not be complete and may have to be amended. The securities may not be sold until a receipt for the prospectus is obtained from the securities regulatory authorities. No securities regulatory authority has expressed an opinion about these securities and it is an offence to claim otherwise. This prospectus constitutes a public offering of these securities only in those jurisdictions where they may be lawfully offered for sale and therein only by persons permitted to sell such securities. These securities have not been, and will not be, registered under the United States Securities Act of 1933, as amended (the ‘‘U.S. Securities Act’’), or the securities laws of any state of the United States and may not be offered or sold, directly or indirectly, in the United States or in any other jurisdiction where the offer or sale of such securities is not permitted, except pursuant to an exemption from the registration requirements of the U.S. Securities Act and applicable state securities laws, or securities laws of any other relevant jurisdiction. This prospectus does not constitute an offer to sell or solicitation of an offer to buy any of these securities in any jurisdiction where the offer, sale or solicitation of an offer to buy any of these securities is not permitted. See ‘‘Plan of Distribution’’.
    [Show full text]
  • Review of Contemporary Knowledge of the Treatment Effects Of
    Review of Contemporary Knowledge of the Treatment Effects of Cannabis and Related Products, and Its Outlook Tomáš Zábranský 1, 4), Lumír Hanuš 1, 2, 4), Richard Rokyta 1, 3, 4) 1) International Cannabis and Cannabinoids Institute, Prague 2) Hebrew University in Jerusalem, Israel 3) Department of Normal, Pathological and Clinical Physiology, 3rd Faculty of Medicine, Charles University in Prague 4) Společnost pro léčbu konopím a kanabinoidy a jejich výzkum, z.s. [Czech Society for Medical Treatment with Cannabis and Cannabinoids and Their Research] CONTENTS CONTENTS .............................................................................................................................................................. 1 ABSTRACT............................................................................................................................................................... 3 KEY WORDS ............................................................................................................................................................ 3 RECOMMENDED CITATION: .................................................................................................................................... 4 INTRODUCTION ...................................................................................................................................................... 4 METHODS ..............................................................................................................................................................
    [Show full text]
  • Patterns of Use of Medical Cannabis Among Israeli
    Vol. 49 No. 2 February 2015 Journal of Pain and Symptom Management 223 Original Article Patterns of Use of Medical Cannabis Among Israeli Cancer Patients: A Single Institution Experience Barliz Waissengrin, MD, Damien Urban, MD, Yasmin Leshem, MD, Meital Garty, BA, and Ido Wolf, MD Institute of Oncology (B.W., M.G., I.W.), Tel Aviv Sourasky Medical Center, Tel Aviv; Institute of Oncology (D.U., Y.L.), Chaim Sheba Medical Center, Ramat Gan; and Sackler Faculty of Medicine (I.W.), Tel Aviv University, Tel Aviv, Israel Abstract Context. The use of the cannabis plant (Cannabis sativa L.) for the palliative treatment of cancer patients has been legalized in multiple jurisdictions including Israel. Yet, not much is currently known regarding the efficacy and patterns of use of cannabis in this setting. Objectives. To analyze the indications for the administration of cannabis among adult Israeli cancer patients and evaluate its efficacy. Methods. Efficacy and patterns of use of cannabis were evaluated using physician-completed application forms, medical files, and a detailed questionnaire in adult cancer patients treated at a single institution. Results. Of approximately 17,000 cancer patients seen, 279 (<1.7%) received a permit for cannabis from an authorized institutional oncologist. The median age of cannabis users was 60 years (range 19e93 years), 160 (57%) were female, and 234 (84%) had metastatic disease. Of 151 (54%) patients alive at six months, 70 (46%) renewed their cannabis permit. Renewal was more common among younger patients and those with metastatic disease. Of 113 patients alive and using cannabis at one month, 69 (61%) responded to the detailed questionnaire.
    [Show full text]
  • Issn 2697-522X
    Vol. 14 No. 4 July - August 2019 ISSN 2697-522X Interdisciplinary Research Review Editorial Board of International Editorial Board of Interdisciplinary Research Review Interdisciplinary Research Review Yongyudh Vajaradul (Editor) Muhammad Yunus (Editorial Board) Pranom Othaganont (Deputy Editor) Manfred Koch (Editorial Board) Sommay Peathanom (Deputy Editor) Jun Yu (Editorial Board) Prabhas Chongstitvatana (Editorial Board) Tou Teck Yong (Editorial Board) Orawon Chailapakul (Editorial Board) Lance Chun Che Fung (Editorial Board) Tuantan Kitpaisalsakul (Editorial Board) Warren Y. Brockelman (Editorial Board) Kanchana Boonsong (Editorial Board) Manfred Hartard (Editorial Board) Sayam Aroonsrimorakot (Editorial Board) Administrative Committees of Journal Wilairat Kirin (Editorial Board) Virat Pingkeaw (President) Wanida Treesawat (Editorial Board) Sommay Peathanom (Vice President) Surapong Charasrosjanakul (Editorial Board) Yongyudh Vajaradul (Committee) Sumnieng Ongsupankul (Editorial Board) Pranom Othaganon (Committee) Porntip Andhivarothai (Editorial Board) Phatcharasak Arlai (Committee and Secretary) Orapun Metadilogkul (Editorial Board) Management and Distribution Section Prasutr Thavornchaisit (Editorial Board) Ladda Khemnark Artcha Boongrapu (Editorial Board) Phatcharasak Arlai (Editorial Board and Secretary) Santi Koonkarnkhai (Manager) Publisher : Research and Development Institute, Nakhon Pathom Rajabhat University, 85 Malaiman road, Amphur Muang, Nakhon Pathom 73000, Thailand Origin : The Interdisciplinary Research Review was
    [Show full text]
  • Annual Information Form
    CRONOS GROUP INC. ANNUAL INFORMATION FORM For the year ended December 31, 2018 DATED: March 25, 2019 TABLE OF CONTENTS GENERAL MATTERS ............................................................................................................................................... 3 FORWARD LOOKING INFORMATION ............................................................................................................... 3 CORPORATE STRUCTURE .................................................................................................................................... 6 GENERAL DEVELOPMENT OF THE BUSINESS ............................................................................................... 7 DESCRIPTION OF THE BUSINESS ..................................................................................................................... 13 ALTRIA STRATEGIC INVESTMENT ................................................................................................................. 39 RISK FACTORS ....................................................................................................................................................... 43 DIVIDENDS AND DISTRIBUTIONS ..................................................................................................................... 76 CAPITAL STRUCTURE .......................................................................................................................................... 76 MARKET FOR SECURITIES ................................................................................................................................
    [Show full text]
  • Cannabis Brands
    Intro-Blue, LLC | 617-454-1088 | [email protected] | www.intro-blue.com | Volume 54 | 7/29/20 CANNABIS BRANDS – THE RACE FOR THE TOP SPOT HAS JUST BEGUN In our June 24 Stash report, we discussed why brand presence, shelf space, and market share are among the key KPIs for cannabis investors to monitor. We had also highlighted that cannabis brands are a state-specific asset, with no dominant brand across U.S. states, suggesting that local brands currently have an edge over national players that are yet to establish themselves as the number one choice of consumers. Our thesis was supported by a July 7 news article in the Marijuana Business Daily which found that the addition in number of cannabis brands in the U.S. is outpacing the increase in retail store count, resulting in increased competition for retail shelf space in key adult-use markets. This is forcing brands to pay slotting fees ranging from $500 to $15,000 per month for premium space on cannabis retailers’ shelves. This pay-to-play practice/slotting fees – especially in key in key states like California and Nevada – has gathered pace with the rise in popularity of cannabis products (especially vape products), implying that consumers are relatively more brand conscious while buying cannabis in other product formats vs. when buying dried flower. Lack of dominant brands is a reality in the Canadian market too, as brand awareness is not translating into higher sales with consumers basing their purchase decisions on price rather than brand names or packaging. Canada legalized sale of cannabis products – Cannabis 2.0 – in December 2019 and a survey of 3,000 cannabis consumers by Brightfield Group found that despite the brand building push by most LPs, the vast majority of brands have awareness levels ranging between just 1% and 15%.
    [Show full text]
  • Medicinal Cannabis Samples
    המחקר של השוני הכימי של חשיש ממקורות שונים שנתפס בישראל לומיר הנוש המכון למדעי התרופה בית הספר לרוקחות 2014 1 The study of chemical differences of hashish from different sources seized in Israel. Lumír Hanuš Institute for Drug Research School of Pharmacy 2014 2 תקציר קנאביס, בצורת הצמח והשרף, הוא הסם הפופולרי ביותר בישראל בשנים האחרונות. עד 5002, היו המקורות העיקריים של שרף הקנביס )הידוע גם כחשיש( בשוק הסמים הישראלי לבנון והודו. החשיש ממקורות אלה יכול להיות מובחן על ידי המראה החיצוני שלו. מטרת מחקר זה הייתה לבדוק האם יש הבדל באיכות החשיש מכל מקור .לצורך כך, כימתנו את הקנבינואידים הראשיים, קנבידיול )CBD(, תתרהידרוקנבינול )THC( וקנבינול )CBN( של חשיש שנתפס בתפיסות משטרה ממקורות ידועים - לבנון, הודו ומרוקו, שהועברו למעבדה לכימיה אנליטית של המחלקה לזיהוי פלילי במטה הארצי של משטרת ישראל, ולאחר מכן לאוניברסיטה העברית לאנליזה כמותית. התוצאות, המבוססות על תפיסות רבות ושונות, הראו כי CBD של חשיש מלבנון השתנה מ26.5%- ל95625%- )ממוצע של THC , )8658 ± 0625% של חשיש מלבנון השתנה מ0650%- ל0650%- )ממוצע של 0652% ± 5608) , CBD של חשיש ממרוקו השתנה מ9625%- ל2690%- )ממוצע של THC ,)0625 ± 0695% של חשיש ממרוקו השתנה מ2608%- ל90609%- )ממוצע של CBD ,)5659 ± 0600% של חשיש מהודו השתנה מ0628%- ל- 90690% )ממוצע של % 9602 ± 0625(, ו-THC של חשיש מהודו השתנה מ0620%- ל9.602%- )ממוצע של .(.602 ± 9620% באותו זמן, זוהו כמה קנבינואידים אחרים, שנמצאו בדגימות בכמות נמוכה יותר )זוהו - cannabidivarol , CBDV 9-tetrahydrocannabivarol - 9-THCV , cannabivarol - CBV , cannabichromene - CBC , monomethyl cannabigerol - CBGM , 8- tetrahydrocannabinol - 8 -THC , cannabielsoin - CBE ו- cannabigerol – CBG( . הדגימות, בעיקר מלבנון, מרוקו והודו, הוערכו לפנוטיפ הכימי )סוג תרופה וסוג סיבים( במטרה לקבוע את המקור הגיאוגרפי של דגימות אלה.
    [Show full text]